CMS says there is insufficient evidence to overturn its 2008 national non-coverage decision on microvolt T-wave alternans (MTWA) sudden cardiac risk stratification testing using the modified moving average (MMA) method, as requested by GE Healthcare.
FDA has approved methods of MTWA testing to stratify the risk of sudden cardiac death in patients with risk factors:...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?